Insider Transactions Reported by 19 Insiders of Immunovant, Inc.

Symbol
IMVT on Nasdaq
Location
New York, NY

Insiders trading volume in the past year

Immunovant, Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Roivant Sciences Ltd. Director, 10%+ Owner $2,379,657,147 +$686,900,186 +41% 12 Dec 2025
Peter Salzmann Chief Executive Officer, Director $17,543,264 -$1,142,829 -6.1% 16 Apr 2025
Frank Torti Director $16,667,378 01 Apr 2025
Julia G. Butchko Chief Development Officer $14,251,795 21 Aug 2024
Mark S. Levine Chief Legal Officer $8,124,353 20 Nov 2024
William L. Macias Chief Medical Officer $7,454,384 -$99,649 -1.3% 19 Feb 2025
Eva Renee Barnett Chief Financial Officer $5,907,965 -$400,661 -6.4% 16 Apr 2025
Melanie Gloria Chief Operating Officer $4,159,058 -$298,237 -6.7% 20 Nov 2025
Michael Geffner Chief Medical Officer $4,147,740 -$310,958 -7% 22 Oct 2025
Christopher Van Tuyl Chief Legal Officer $4,105,083 -$290,943 -6.6% 18 Dec 2025
Jay Stout Chief Technology Officer $3,821,490 -$296,142 -7.2% 22 Oct 2025
Tiago Girao Chief Financial Officer $3,059,135 01 May 2025
Douglas J. Hughes Director $2,893,721 -$348,665 -11% 01 Dec 2025
GEORGE V. MIGAUSKY Director $2,739,530 01 Apr 2025
Atul Pande Director $2,452,106 01 Apr 2025
Andrew J. Fromkin Director $2,056,155 -$673,958 -25% 01 Dec 2025
Robert Susman Director $367,234 01 May 2025
Jake Bauer Director $367,234 01 May 2025
Eric Venker Chief Executive Officer, Director 28 Jul 2025

Recent Insider Transactions by Companies or Individuals for Immunovant, Inc.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.